Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03463161
Title Epacadostat and Pembrolizumab in Patients With Head and Neck Cancer That Have Failed Prior Immunotherapy (ORKA)
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of Chicago
Indications

head and neck squamous cell carcinoma

Therapies

Epacadostat + Pembrolizumab

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.